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Latency is a state of cryptic viral infection associated with genomic persistence and highly restricted gene
expression. Its hallmark is reversibility: under appropriate circumstances, expression of the entire viral
genome can be induced, resulting in the production of infectious progeny. Among the small number of virus
families capable of authentic latency, the herpesviruses stand out for their ability to produce such infections
in every infected individual and for being completely dependent upon latency as a mode of persistence.
Here, we review the molecular basis of latency, with special attention to the g-herpesviruses, in which the
understanding of this process is most advanced.Introduction
Although many viruses are capable of subclinical infection, only
a few are known to undergo true latency. In latent infection, the
full viral genome is retained in the host cell, but its expression
is dramatically restricted, such that few viral antigens and no viral
particles are produced. To qualify as latency, this cryptic form of
infectionmust display two additional properties: persistence and
reversibility. Reversibility—i.e., the capacity of the genome to re-
activate full viral gene expression, with production of infectious
progeny (so-called productive or lytic replication)—is the key
requirement of latency. Cryptic states that lack this character-
istic are more properly characterized as abortive infections,
which typically occur when viruses infect cells that are nonper-
missive for viral replication. Efficient establishment of latency
allows the viral genome to persist despite host immune
responses to many viral antigens and in the face of other poten-
tially adverse signals in the microenvironment. When environ-
mental conditions warrant, appropriate signals can trigger the
reversal of latency, allowing virus production and spread to
resume.
Only a few virus families are known to be capable of true
latency, as strictly defined above. Chief among these are the
herpesviruses, a huge and widely distributed family of DNA
viruses that are important pathogens in their native vertebrate
hosts. The capacity for latency is a defining feature of herpes-
viruses: all known herpesviral infections display latency in every
infected individual. Indeed, the anatomic sites of latency and
the frequency with which latency is reversed to engender lytic
infection are important determinants of the clinical manifesta-
tions of infection. While retroviruses are also capable of
latency, the role of latency in the natural history of infection
and its fundamental molecular mechanisms are best under-
stood among the herpesviruses, which therefore will be the
focus of this review.100 Cell Host & Microbe 8, July 22, 2010 ª2010 Elsevier Inc.Herpesviral Infection: A Primer
Herpesviruses are large, enveloped DNA viruses that can
engender either a latent or a lytic infection at the level of the
single cell. Three major subfamilies of herpesviruses—termed
a, b, and g—are recognized based on sequence phylogeny.
The a-viruses establish latent infections in neurons while the
g-herpesviruses are markedly lymphotropic (the tropism of the
b-herpesviruses is more variable). Among the a- and b-viruses,
lytic infection is the default pathway in culture; in fact, we lack
cell culture models of latent infection for virtually all of these
agents. As a result, although our understanding of their lytic repli-
cation is very advanced,much less is known about themolecular
basis of their latent states. Formost a- and b-viruses, latency can
be studied only in an intact human or animal host. This poses
a formidable experimental barrier to mechanistic understanding
of latency, since relatively few latently infected cells exist in any
given tissue.
By contrast, among the g-herpesviruses, latency is generally
(though not invariably) the default pathway in cell culture. As a
result, it is usually straightforward to obtain substantial popula-
tions of latently infected cells following in vitro infection, facili-
tating the analysis of both viral and host gene expression in
such populations, as well as analyses of the details of viral
genome and chromatin structure. For all of these reasons, more
is known about latency in the lymphotropic subgroup than in
any of their more distant relatives. Accordingly, in this review
we will focus on how g-herpesvirus latency is established and
maintained and how these processes are regulated.
Common Features of the g-Herpesviral
Replication Cycle
All g-herpesviruses, including Epstein-Barr virus (EBV), Kaposi’s
sarcoma-associated herpesvirus (KSHV), and murine g-herpes-
virus 68 (MHV68), encapsidate duplex linear DNA genomes in
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nucleus, where it is circularized (largely by host enzymatic
machinery), generating a closed-circular DNA form that can
persist in the nucleus as a plasmid. Incoming virion DNA gener-
ally lacks histones, but the resulting plasmid is rapidly chromati-
nized in the nucleus (Tempera and Lieberman, 2010). Since
latency is generally the default pathway in this group, most viral
gene expression from the plasmid must be silenced, with only
a handful of genes being expressed from the latent genome.
As a general rule, one or more of these genes directs replication
of the viral genome, using a cis-acting sequence (termed oriP) as
the replication origin of the plasmid. Several latency genes are
involved in modulation of host signaling, most notably influ-
encing the activation of NF-kB, which turns out to be important
in the maintenance of latency (see below). Interestingly, how-
ever, these common functions are often carried out by viral
proteins that share little homology across the different g-herpes-
viruses. For example, none of the latency proteins of EBV are
conserved in KSHV or MHV68 (though the latter two viruses do
share a number of latency genes).
As noted above, latency is reversible. Because the full comple-
ment of viral DNA is retained in the nucleus, under the appropriate
circumstances, the second program of viral gene expression,
lytic replication, can be activated. In this program, expression
of most of the remaining viral open reading frames (ORFs) is
activated in a temporally regulated cascade. In contrast to the
latencygenes, there is extensiveconservationof lytic cycle genes
across all herpesviruses. In all three viruses under review here,
lytic reactivation is controlled by one (sometimes more) master
regulator of transcription. Expression of these so-called lytic
switch protein genes is silenced in latency but is turned on by
all signals that trigger lytic reactivation; this activator, in turn, trig-
gers expression of downstream genes to kickstart the lytic cycle.
g-herpesviruses thus face a number of common problems that
must be solved in order for latency to be established and main-
tained. First, incoming viral genomesmust be chromatinized and
epigenetic and genetic controls established that allow for the
latent transcriptional program. Second, latency functions must
provide for stable replication from oriP and for mechanisms to
ensure segregation of the viral genome to daughter cells if the
latently infected cell should divide. Third, latent regulators of
signaling must create an environment that fosters the stability
of latency without rendering it irreversible. Finally, in the intact
host, successful latency may also require modulation of host
cell functions, particularly those affecting the life span and prolif-
erative potential of the latently infected cell. Our molecular
understanding of all of these issues is still very incomplete, but
some unifying themes are starting to come into view. Even
though the latency proteins are poorly conserved among the
viruses, commonalities in the modes by which they promote
episome maintenance and in the signaling pathways they
engage are emerging. In what follows, we discuss in detail the
latency strategy of three individual g-herpesviruses, with partic-
ular attention to these themes and their variations.
EBV Latency and Its Control
The EBV Latency Programs
EBV was the first identified g-herpesvirus and remains the best-
characterized member of this family. Initially recovered from celllines derived from African Burkitt’s lymphoma (BL) in the 1960s,
EBV has since been associated with a variety of lymphoprolifer-
ative diseases and lymphomas as well as other nonlymphoid
cancers (see Rickinson and Kieff [1996] for review). In vitro and
in vivo, the primary target of EBV infection is the B cell; following
de novo infection of B cells in culture, latency is the default path-
way. In vitro infection of primary B cells often results in immortal-
ization, and the resulting lymphoblastoid cell lines (LCLs) have
been an important source of information about EBV latency
(see Rickinson and Kieff [1996] for review). However, EBV
latency is a complex subject that can present several different
faces, not all of which are captured by the study of LCLs.
The Growth Program. The discovery that EBV could efficiently
immortalize primary B cells to LCLs had a major impact on the
field, since it (1) provided a ready source of latently infected B
cells and (2) appeared to cement the relationship between EBV
infection and the genesis of BL. Characterization of viral genes
expressed in such LCLs (see Bornkamm and Hammerschmidt
[2001] for review) led to the identification of viral proteins, along
with several noncoding RNAs, that were consistently detected.
The viral proteins expressed in LCLs can be broken into two
distinct groups: six nuclear antigens (Epstein-Barr nuclear anti-
gens, EBNA-1, -2, -3a, -3c, -3b, and -LP) and three membrane
antigens (latency-associated membrane proteins, LMP-1, -2a,
and -2b). The viral genes expressed during latency are not clus-
tered in a single region but rather are spread out over most of the
genome. However, the promoters and cis-elements controlling
these genes are in fact clustered in a relatively small region span-
ning the fused terminal repeats (TRs) of the viral episome (see
Figure 1).
During the initial phase of EBV infection, EBNA gene transcrip-
tion is initiated from a promoter, Wp, located within the major
internal repeat of the virus (IR1; 3 kb repeat length) (see Speck
[2005] and references therein). There are multiple copies of
Wp, which collectively appear to function as an ‘‘ignition switch’’
to launch EBNA gene transcription in the newly infected resting B
cell. Themost proximal EBNA genes, EBNA-LP and EBNA-2, are
the first viral proteins expressed and function together to drive
a switch to a second promoter located just upstream of the
IR1 repeat region, termed Cp (see Speck [2005] and references
therein), which then drives expression of the remaining EBNAs.
This switch is driven by the interaction of EBNA-2 with the
cellular transcription factor RBP-Jk (also known as CBF-1 and
CSL), which normally functions in the regulation of genes in the
cellular Notch signaling pathway (see Hayward [2004] for
review). EBNA-2’s interaction with RBP-Jk also serves to turn
on transcription of the LMP genes.
An important product of the Cp transcripts is EBNA-1, which
plays a central role in latency by binding to sequences in oriP
and promoting initiation of episomal DNA replication of the viral
episome, a process largely effected by cellular enzymes and
one that proceeds in concert with host DNA replication (Yates
et al., 1985; Reisman et al., 1985). In addition to this function,
EBNA-1 also plays important roles in plasmid segregation in
dividing cells via its ability to bind both the viral genome and
metaphase host chromosomes. As a result, the viral genome is
tethered to host chromosomes and can therefore be passively
distributed with them to daughter cells by the workings of the
mitotic spindle. Mutational lesions in regions of EBNA-1 thatCell Host & Microbe 8, July 22, 2010 ª2010 Elsevier Inc. 101
Figure 1. Schematic Illustration of EBV EBNA and LMPGene Transcription and Autoregulation of Viral Latency-Associated Gene Expression
by the EBNA Gene Products
An exploded view of Cp- and Wp-driven EBNA gene transcription is shown, depicting the organization of exons immediately downstream of each promoter.
Cp-initiated transcript contains two unique exons, C1 and C2, which splice to a variable number of W1 andW2 exons encoded within the 3.0 kb internal repeats.
Wp-initiated transcript contains a single unique exon,W0, which splices to a variable number ofW1 andW2 repeat exons. See text for additional details regarding
EBV gene expression during different stages of infection. Also shown in the inset is the predicted membrane topology of the LMP-1 and LMP-2a proteins, along
with known cellular-interacting partners and signaling pathways activated by these proteins.
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episomes in dividing cells (Sears et al., 2004).
In addition to its replicative functions, EBNA-1 is also a tran-
scriptional activator. When bound to oriP sequences, which
are just upstream of Cp, it can upregulate transcription from
this promoter (see Speck [2005] and references therein). Thus,
the switch from Wp to Cp reflects a shift from utilizing a viral
promoter regulated by cellular transcription factors to one that
is tightly controlled by viral factors.
Which of the nine latency-associated proteins are required for
EBV immortalization of primary human B cells? Multiple studies
have shown a requirement for EBNA-1, EBNA-2, EBNA-3a,
EBNA-3c, and LMP-1, while EBNA-3b and LMP-2a/b appear
dispensable (reviewed in Bornkamm and Hammerschmidt
[2001]).EBNA-LP may also contribute to immortalization, since
deletion of the unique C-terminal 45 aa of EBNA-LP has been102 Cell Host & Microbe 8, July 22, 2010 ª2010 Elsevier Inc.shown to significantly impair LCL formation (Mannick et al.,
1991). LMP-1 is a particularly important latency function;
a member of the TNF superfamily, it consitutively upregulates
NF-kB activity (Izumi and Kieff, 1997), potently affecting B cell
survival (Bornkamm and Hammerschmidt, 2001).
Alternative Latency Programs. While the early studies on
EBV-immortalized LCLs and established BL tumor cell lines sup-
ported the notion of a direct role for EBV-driven B cell prolifera-
tion in the genesis of BL, amore careful analysis of fresh BL biop-
sies and early-passage BL cell lines revealed a much more
restricted pattern of EBV gene expression (see Rickinson and
Kieff [1996] for review). In the vast majority of BL tumors, the
only viral antigen that can be detected is EBNA-1 (this is now
referred to as type I latency). Subsequent analyses of both naso-
pharyngeal carcinomas and EBV-positive Hodgkin’s lymphomas
revealed another restricted pattern of viral gene expression, in
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could be detected (now termed type II latency; the larger,
growth-promoting program of LCLs is now designated type III
latency) (see Rickinson and Kieff [1996] for review). In all of these
tumors, the common theme was expression of EBNA-1 in the
absence of the other EBNA genes. Since all EBNA gene tran-
scription in EBV LCLs is driven from a single transcriptional
unit, this raised the question of how the EBNA-1-only programs
were regulated. This ultimately led to the identification of an alter-
native promoter, Qp, located downstream of the EBNA-2 coding
exons (Schaefer et al., 1995). Notably, Qp-initiated transcripts
splice exclusively to the EBNA-1 coding exon, bypassing the
exons encoding the EBNA-3 family of nuclear antigens (Figure 1).
How this selectivity in splice site selection is achieved remains
a mystery.
While EBNA-1 upregulates EBNA and LMP gene expression
through binding to oriP, it potently inhibits transcription from
Qp (Sample et al., 1992). A genome-wide survey for EBNA-1
binding sites in the EBV genome revealed only two sites outside
oriP, both of which map just downstream of the Qp transcription
initiation site (Jones et al., 1989). Unlike Cp and Wp, Qp is a
TATA-less promoter that appears related to promoters found
upstream of housekeeping genes, suggesting that it may func-
tion as the default promoter to ensure ongoing expression of
EBNA-1 in the absence of transcription initiation from Cp and/
or Wp (Schaefer et al., 1995, 1997).
Given what we know about autoregulation of EBNA gene
expression (see above), how is Cp/Wp-initiated EBNA gene tran-
scription silenced in the EBV-associated tumors that arise in
immunocompetent individuals? A large number of studies have
shown that Cp and Wp are heavily methylated in these tumors,
while Qp remains unmethylated and active (for review, see Tao
and Robertson [2003]). The importance of DNA methylation in
the suppression of Cp/Wp transcriptional activity in BL cell lines
is supported by three independent experimental observations:
(1) the drift of some BL cell lines to expression of all the EBNA
and LMP genes (type III latency) correlated with the loss of meth-
ylation around Cp and Wp, (2) inhibition of DNA methyltransfer-
ase activity induces transcription from Cp/Wp in BL cell lines ex-
hibiting the type I latency program, and (3) reporter constructs
containing extensive sequence upstream and downstream of
Cp are active when transfected into BL cell lines exhibiting the
type I latency program. The latter result argues that cells in
latency type I contain the necessary transcription factors to drive
Cp/Wp-initiated transcription but are prevented from doing so
because the viral genomes aremethylated and in a transcription-
ally inactive conformation.
EBV Latency in Its Natural Context
All of the above studies reflect analyses of EBV latency in the
highly abnormal context of EBV-induced tumors or LCLs. But
what does latency look like in the majority case—i.e., persistent
EBV infection of healthy seropositive individuals? Thorley-Law-
son and colleagues have shown that in the peripheral blood of
such individuals, EBV is found exclusively in resting memory B
cells (CD20+, CD27+, CD5, CD10, IgD) and not in activated
lymphoblasts (Babcock et al., 1998). Analysis of viral gene
expression in these resting memory B cells failed to detect
expression of the viral antigens associated with the EBV growth
program (type III latency), save for the sporadic detection ofEBNA-1 transcripts, which are initiated from Qp (for review,
see Thorley-Lawson [2001] and Thorley-Lawson et al. [2008]).
The latter appear to correspond to circulating memory B cells
that have recently undergone a round of cell division.
How does EBV get into the memory B cell pool? Examination
of tonsil tissue has revealed the presence of EBV infection in: (1)
naive B cells (CD19+, sIgD+), which exhibit a lymphoblastoid
phenotype and display type III latency; (2) germinal center B
cells, which exhibit a type II latency program; (3) proliferating
memory B cells (EBNA-1 only; type I latency); and (4) plasma
cells, in which EBV enters the lytic cycle (see discussion below)
(Thorley-Lawson et al., 2008). Thus, EBV infection in germinal
center B cells largely recapitulates the viral gene expression
program in EBV-positive Hodgkin’s lymphoma tumors, while
EBV infection in cycling memory B cells recapitulates the latency
program observed in endemic BL tumors. Why has EBV evolved
this complicated set of latency programs? Based on these snap-
shots of EBV gene expression in distinct B cell populations, it has
been proposed that EBV hijacks normal B cell differentiation to
gain access to the memory B cell pool (see Figure 2). This model
postulates that virus infection of naive B cells results in the
generation of activated lymphoblasts that appear phenotypically
similar to antigen-activated lymphoblasts (Thorley-Lawson et al.,
2008). Some of these virus-infected lymphoblasts then form and/
or participate in germinal center reactions, in which LMP-1
expression provides signals that mimic CD4+ T cell help (CD40
signaling) while LMP-2a provides signals thatmimic the essential
survival signals normally provided by the B cell receptor, allow-
ing EBV-infected B cells to transit through the germinal center
reaction. The only other viral antigen expressed in EBV-infected
germinal center B cells is EBNA-1, which serves to maintain the
viral episome in proliferating germinal center B cells. From these
germinal centers, EBV-infectedmemory B cells and plasma cells
emerge. The memory B cells that exit the lymphoid tissue and
enter the periphery then stop cycling and shut off EBNA-1
gene transcription, presumably due to the accumulation of
EBNA-1, which negatively feedbacks on Qp, shutting down
EBNA-1 gene transcription. Analysis of viral genomemethylation
in B cells isolated from peripheral blood of healthy seropositive
individuals revealed that, like the status of the viral genome in
BL and Hodgkin’s lymphoma tumors, Cp andWp aremethylated
while Qp is protected from methylation (Paulson and Speck,
1999).
In summary, EBV has evolved a complex set of latency
programs that allows the virus to navigate from infection of naive
resting B cells (the dominant B cell population that the virus
encounters during the initial stages of infection) to ultimately
gain access to the memory B cell reservoir. In this process,
EBV takes advantage of an ancient host antimicrobial strategy—
host cell-driven DNA methylation—to strategically silence viral
gene expression as infection progresses from a naive B cell to
the germinal center reaction. In addition to methylation of the
viral genome, modulation of NF-kB activity and manipulation of
the Notch signaling pathway through interaction with the host
DNA-binding protein RBP-Jk/CBF-1/CSL represent two key
prosurvival and progrowth pathways targeted by EBV. The end
goal, establishing latency in memory B cells, clearly affords the
virus a long-lived cell type in which to persist and avoid immune
detection.Cell Host & Microbe 8, July 22, 2010 ª2010 Elsevier Inc. 103
Figure 2. Model Depicting the Different EBV Latency Programs Expressed during the Progression of Infected Naive B Cells through
a Germinal Center Reaction and Establishment of Latency in Memory B Cells
Also shown is virus reactivation linked to plasma cell differentiation. See text for additional details.
Cell Host & Microbe
ReviewKSHV Latency and Its Control
An Overview
KSHV (also called human herpesvirus 8) was discovered in 1994
in a search for viral agents in Kaposi’s sarcoma, a neoplasm of
endothelial cells. Subsequent epidemiologic research affirmed
the etiologic link to KS (see Cohen et al. [2005] for review), but
also revealed that phylogenetically, KSHV belongs to the lym-
photropic herpesviruses. This triggered a search for KSHV
DNA in a variety of lymphoproliferative diseases and led to its
linkage to two disorders of B cells: primary effusion lymphoma
(PEL) and multicentric Castlemen’s disease (MCD) (Cesarman
et al., 1995; Soulier et al., 1995). Although these are rare
sequelae of KSHV infection, they reflect the fact that in healthy
seropositive hosts, CD19+ B cells appear to be the primary
target of KSHV infection (Ambroziak et al., 1995).
KSHV can efficiently infect many adherent cell lines in culture,
including endothelial cells, fibroblasts, and epithelial cells. As in
EBV, the default pathway following these in vitro infections is
latency. Paradoxically, however, KSHV stocks do not initiate
infection of established B cell lines—e.g., BL lines or EBV-
induced LCLs (Bechtel et al., 2003). Why this is so is unclear,
but it has been a major impediment to the study of lymphoid
infection by KSHV. However, two recent studies have reported104 Cell Host & Microbe 8, July 22, 2010 ª2010 Elsevier Inc.the infection of primary B cells in vitro. If such B cells are derived
from the peripheral blood, they must first be activated by treat-
ment with IL4 and CD40 ligand (Rappocciolo et al., 2008).
However, B cells derived from tonsils can be infected without
such pretreatments, probably reflecting the fact that tonsillar
cells are already highly activated in vivo (J. Myoung and D.G.,
unpublished data). In both situations, and in striking contrast to
EBV infection of primary B cells in vitro, no immortalization of B
cells follows KSHV infection. In fact, KSHV latency in all cell types
lacks immortalizing activity, indicating that KSHV has no analog
of the EBV growth program (latency III). Indeed, none of the
known EBV latency genes have homologs in KSHV.
The KSHV genome, as extracted from the virion, is a linear
duplex of 165 kb (Renne et al., 1996a). Coding regions bearing
at least 87 ORFs comprise the central 140 kb of the genome
and are flanked by extensive, noncoding, GC-rich TRs (Lagunoff
and Ganem, 1997). Following infection, as in EBV, the genome
circularizes in the nucleus and, in latently infected cells, is
maintained as a chromatinized nuclear plasmid. Latent DNA
replication proceeds from an origin (oriP) in the TRs (Ballestas
et al., 1999; Ballestas and Kaye, 2001; Hu et al., 2002), and the
genome is maintained at relatively low copy numbers. Latency
in PEL cells is quite stable, with <1%–3% of cells displaying
Figure 3. Major Latency Locus of KSHV
Top line: Major ORFs of the locus. ORF-73 encodes LANA; ORF-72 encodes v-cyclin (v-CYC); ORF-71 encodes v-FLIP; ORF-K12 encodes Kaposin A; DRs 1 and
2 encode direct repeats in which translation of Kaposins B and C initiate. LIR, long interspersed repeats of unknown function. Middle panel: KSHV miRNA (miR)
cluster, with pre-miRNAs indicated by arrowheads. Bottom panels: Structures of mRNAs directed by the Kaposin (or LTd) promoter and by the LANA (or LTc)
promoter. Figure modified with permission from Ganem (2010).
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at a higher frequency by a variety of exogenous stimuli and is
controlled by a virus-encoded master regulatory protein, RTA,
by mechanisms discussed below (see Exit from Latency).
The Latency Program of KSHV
Examination of latent infection in B cell lines derived from PEL
has led to recognition of a major latency locus that is abundantly
and consistently transcribed in all latently infected cells. This
region includes four ORFs, encoding LANA (latency-associated
nuclear antigen), v-cyclin, v-FLIP (Flice-inhibitory protein), and
the kaposin protein family (Figure 3). The first three genes are
under the control of a single promoter (the LANA promoter, or
LTc), which generates a series of coterminal mRNAs via differen-
tial splicing (Dittmer et al., 1998). A second promoter (the kaposin
promoter, or LTd), located just downstream of LANA, encodes
a spliced transcript encoding the kaposins (Li et al., 2002; Pearce
et al., 2005; Cai and Cullen, 2006) and can also generate a bicis-
tronic RNA for v-cyclin and v-FLIP. This promoter also governs
the expression of 12 pre-miRNAs, which can be processed to
yield a total of 18 mature miRNAs (Umbach and Cullen, 2010).
All of these latent products are found to be expressed in KS
spindle and PEL cells (Dittmer, 2003; Marshall et al., 2007;
Hansen et al., 2010).
A second, unlinked locus expressed in latent PEL cells
encodes the v-IRF3 (or LANA-2) protein, a member of the IRF
superfamily that dominantly inhibits the function of certain
cellular IRFs and thereby blocks interferon induction (Rivas
et al., 2001). This gene has to date been found to be expressed
only in PEL cells and not in KS cells, indicating that some latency
genes may be lymphoid specific.
Very recently (Chandriani and Ganem, 2010), a third latent
locus has been identified that encodes the K1 protein. This
gene is transcribed at exceedingly low levels in latency and is
upregulated during lytic growth. K1 is an interesting protein,
because it is a constitutively acting signaling molecule that
mimics signaling via the B cell antigen receptor (Lee et al.,
2005). This is formally analogous to the output of EBV’s LMP-2
and raises the question of whether K1 and LMP-2 play similarroles in the natural history of persistent B cell infection. At
present, however, too little is known regarding KSHV latency in
its human host to know if this analogy is accurate—we do not
know, for example, whether KSHV infects germinal center B cells
or whether it goes on to establish residence in long-livedmemory
B cells.
In the following sections, we focus on the latent KSHV
gene products whose functions have been most intensively
investigated.
LANA. This viral protein clearly plays a role in the persistence
and segregation of the latent viral episome that is formally
analogous to that of EBNA-1 (Ballestas et al., 1999). LANA is
a large polypeptide with a unique C-terminal domain containing
a sequence-specific DNA-binding region that recognizes con-
served sequences within the TRs of viral DNA (Ballestas and
Kaye, 2001; Garber et al., 2001). LANA binding to the TRs, which
represents the core of the replication origin of the latent viral
plasmid (oriP), is required for episome replication during latency,
just as EBNA-1 is in EBV (Hu et al., 2002). Like EBNA-1, LANA
also plays a role in the segregation of viral plasmids to daughter
cells in proliferating cells (Ballestas et al., 1999; Cotter and
Robertson, 1999). The N-terminal domain of LANA contains
motifs primarily responsible for its adherence to metaphase
chromosomes (Piolot et al., 2001), principally via interactions
with histones H2A and H2B (Barbera et al., 2006). By interacting
with mitotic chromosomes on the one hand and viral episomes
on the other, LANA can effectively tether the KSHV genome to
host chromosomes and allow KSHV DNA to ‘‘hitch a ride’’ to
daughter nuclei during mitosis. This function is critical to viral
persistence in rapidly proliferating cells, like PEL cells in vivo or
immortalized cells in culture.
However, while episome maintenance in PEL cells is very
stable, the same may not be true of other latently infected cells.
When most actively growing cell lines are infected in culture,
KSHV genomes are rapidly lost unless a genetic selection is
applied for their maintenance (Grundhoff and Ganem, 2004).
Thus, the LANA/oriP system functions inefficiently in most cells;
additional cis-acting epigenetic modifications are required toCell Host & Microbe 8, July 22, 2010 ª2010 Elsevier Inc. 105
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et al., 2007a). The exact nature of these modifications has not
yet been determined. Presumably, stably latent PEL cells have
undergone these adaptations in vivo, while most other infected
cells, in which latency is unstable, have not.
What does all this mean for latency in its natural context, the
healthy KSHV-seropositive individual? We don’t yet know, since
the nature of the infected B cell in latency is still not established.
If, as in EBV, latency primarily resides in infrequently dividing
memory B cells, then there may have been no compelling evolu-
tionary selection for a highly efficient system for plasmid mainte-
nance. Interestingly, the EBV EBNA-1/oriP system also displays
remarkable instability in the absence of a genetic selection
(Leight and Sugden, 2001), suggesting that the EBV and KSHV
latency maintenance machines may function in a closely similar
fashion despite wide divergence in structure.
In addition to its function in viral plasmid maintenance, LANA
has additional activities that may also more directly influence
the behavior of latently infected cells. Isolated LANA expression
outside the context of infection reveals that the protein inhibits
p53 activity (Friborg et al., 1999), which might promote the
survival of latently infected cells. LANA also binds Rb and
impairs Rb function (Radkov et al., 2000). Another LANA inter-
action partner is GSK-3b, a kinase that targets the cytosolic
protein b-catenin for ubiquitination and proteasomal destruc-
tion (Fujimuro et al., 2003); this interaction upregulates b-cate-
nin and triggers a transcriptional program promoting S phase
entry.
LANA also has regulatory effects on transcription that poten-
tially could influence the maintenance of latency. When LANA
is directly bound to DNA, it can repress transcription of adjacent
reporter genes (Schwam et al., 2000). LANA has therefore been
proposed to negatively regulate viral lytic gene transcription
(Li et al., 2008) and thereby influence the control of latency. It
is important to realize, however, that most cells infected by
LANA deletion mutants of KSHV do not spontaneously enter
the lytic program (Li et al., 2008), indicating that there is more
to latency control than negative regulation of the lytic cycle by
LANA.
V-Cyclin. The major latency locus also encodes v-cyclin, the
product of ORF-72 and a viral homolog of cellular cyclin D
(Chang et al., 1996). Like its cellular homolog, v-cyclin activates
cdk6; it can also reduce regulation of cdk6 by CDK inhibitors
(Swanton et al., 1999). Although v-cyclin’s in vitro activities
are consistent with cellular growth promotion, this predicted
effect has been difficult to affirm experimentally. For example,
although v-cyclin expression in primary endothelial cells trig-
gered enhanced S phase entry (and centrosome amplification),
this was followed by activation of a DNA damage response char-
acterized by induction of antiproliferative checkpoint mecha-
nisms (phosphorylation of ATM andChk2 kinases), p53 stabiliza-
tion, and potent growth arrest, with later induction of cellular
senescence (Koopal et al., 2007). Many of these features were
reproduced by infection of primary ECs with KSHV itself, indi-
cating that this was not simply the result of v-cyclin overexpres-
sion and that p53 inhibition by LANA is insufficient to counteract
this response. Taken together, the findings indicate that the
primary effects of experimental v-cyclin expression are to induce
replicative stress. It is unclear if these effects are merely artifices106 Cell Host & Microbe 8, July 22, 2010 ª2010 Elsevier Inc.of cell culture or reflect the true biological activity of v-cyclin. We
are deeply in the dark about the function of this enigmatic protein
in vivo.
V-FLIP. The third gene in the major latency cluster encodes
v-FLIP, a small polypeptide composed of two tandem death
effector domains (DEDs). KSHV v-FLIP potently activates
NF-kB (Chaudhary et al., 1999) via binding to the NEMO (or
g) subunit of the IkB kinase (IKK) (Liu et al., 2002; Field et al.,
2003).
NF-kB activation by v-FLIP has a number of consequences for
latency. First, it antagonizes entry into the lytic cycle in many (but
not all) cells, thereby stabilizing latency. Chemical (Brown et al.,
2003) or genetic (Grossmann and Ganem, 2008) inhibition of
NF-kB activation enhances spontaneous production of lytic
markers, as does siRNA-mediated knockdown or mutational
ablation of v-FLIP expression (Zhao et al., 2007; Ye et al.,
2008). It is noteworthy that activation of NF-kB figures promi-
nently in the latency programs of all three g-herpesviruses under
review. In EBV, LMP-1 is a strong constitutive activator of NF-kB,
and LMP-1 signaling inhibits lytic reactivation from latency (Adler
et al., 2002). Similarly, evidence from MHV68 suggests that in
that system as well, NF-kB activation is necessary to stabilize
latency (see below and Krug et al. [2007]).
In addition to its stabilizing effects on latency, NF-kB is known
to activate a proinflammatory and antiapoptotic program in
many cell types (Xu and Ganem, 2007; Sakakibara et al., 2009;
Thurau et al., 2009). Since infected endothelial cells are not
immortalized in vitro, it is difficult to assess the contribution of
v-FLIP’s antiapoptotic signaling to endothelial cell life span in
KS; however, it does make endothelial cells resistant to anoikis
in vitro (Efklidou et al., 2008). However, ongoing v-FLIP expres-
sion is critical for B cell survival in PEL—siRNA knockdown of
v-FLIP (or inhibition of NF-kB activation) in otherwise immortal
PEL cells triggers prompt B cell death (Guasparri et al., 2004;
Keller et al., 2000).
The Kaposin Locus
The other major transcription unit active in latency encodes the
Kaposin family of proteins and a series of viral miRNAs. As
summarized in Figure 3, the latent Kaposin promoter generates
a major spliced mRNA whose body encompasses two sets of
23 nt direct repeats (DRs) of GC-rich sequences followed by a
short (60 codon) ORF called ORF-K12, which encodes a two-
transmembrane domain polypeptide called Kaposin A. DRs
can also engender protein products via translational initiation
at CUG codons in their midst to generate Kaposin B, a small
polypeptide derived largely by translation of DR1 and DR2
sequences (Sadler et al., 1999).
Kaposin A. Kaposin A is a small hydrophobic polypeptide
found on intracellular and cell surface membranes. It initially
attracted attention because overexpression of this ORF in
immortalized but untransformed rodent fibroblasts led to (ineffi-
cient) transformation in culture (Muralidhar et al., 1998). This
makes kaposin A an obvious candidate for a role in growth
deregulation in KS and PEL, though the fact that KSHV latent
infection does not immortalize or transform cells means that
the result cannot be directly transposed to explain KSHV tumor-
igenesis in vivo. How Kaposin A functions has remained some-
thing of an enigma. The best data indicate that Kaposin A binds
cytohesin-1, a GEF for ARF family GTPases and a regulator of
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recently, Kaposin A has been found to bind and inhibit septin
4, a putatively proapoptotic caspase 3 activator (Lin et al., 2007).
Kaposin B. This small protein consists largely of sets of 23 aa
proline- and arginine-rich repeats derived from translation of
DRs 1 and 2. Its simple amino acid composition and lack of
known catalytic motifs suggested that it likely serves as a scaf-
fold or adaptor protein, prompting searches for interacting
proteins. The best understood of these is MAP kinase-associ-
ated protein kinase 2 (MK2), a target of the p38 signaling
pathway. Importantly, binding of MK2 by kaposin B is an acti-
vating event, promoting its phosphorylation by p38 and
thereby stimulating cytokine release during latency (McCor-
mick and Ganem, 2005). As such, Kaposin B, like v-FLIP,
contributes to the proinflammatory microenvironment that
characterizes KS.
But these latent proinflammatory activities raise a deeper
paradox. Inmost large DNA viruses, gene products have evolved
to blunt rather than foster host inflammatory and immune
responses (Johnston and McFadden, 2003). Viral evolution is
driven principally by factors influencing virus replication and
spread; pathogenesis and disease is a sideshow, of relevance
only in situations (e.g., respiratory tract infection or diarrhea)
where disease promotes viral spread. The rarity of KS relative
to infection by KSHV (see above) means that KS itself can play
no major role in the evolutionary shaping of the viral genome.
We can reasonably infer that something about an inflammatory
microenvironment is advantageous to KSHV replication and
spread, but the bases of these beneficial effects remain
unknown.
Viral MicroRNAs. As shown in Figure 3, the Kaposin transcrip-
tion unit also encodes 12 pre-miRNAs, ten of which emanate
from the intron of the latent Kaposin mRNA (the remaining two
are found in the body of the transcript) (Cai et al., 2005; Samols
et al., 2005; Cai and Cullen, 2006; Pfeffer et al., 2005). These pre-
miRNAs are conserved in all isolates of KSHV (Marshall et al.,
2007), but are not conserved in other herpesviruses (Sch€afer
et al., 2007). The 12 KSHV pre-miRNAs actually engender 18
mature miRNAs (Umbach and Cullen, 2010), primarily because
a number of them can donate both strands of their hairpin
precursors to the RNA-induced silencing complex, RISC.
Because they are expressed in latency, they have the opportu-
nity to target both cellular and viral mRNAs and could thus influ-
ence the phenotype of latently infected cells in many ways.
Studies to identify the target transcripts of these miRNAs are
in their infancy. Several KSHV miRs appear to downregulate
thrombospondin, a known antagonist of angiogenesis—as such,
they could contribute to the neovascular phenotype of KS
(Samols et al., 2007). OthermiRNAs appear to affect the differen-
tiation state of the host cell. One of these, miRK11, shares seed
sequence identity with a lymphoid-specific hostmiRNA (miR155)
whose targets affect B cell differentiation (Skalsky et al., 2007b;
Gottwein et al., 2007); this finding is particularly interesting given
the known connection of lytic reactivation to B cell differentiation
(see Exit from Latency, below). miRNAs K11 and K6-5p also
downregulate the transcription factor MAF, which affects the
differentiation state of microvascular endothelium (Hansen
et al., 2010). Deletion of most viral miRNAs leads to modest
enhancement of spontaneous lytic reactivation, suggestinga role for the mIRs in regulating the stability of latency (Lei
et al., 2010). One, miRK9-5p (formerly miRK9*), targets a
sequence in the 30 UTR of RTA; functional inactivation of this
miRNA leads to a 2- to 3-fold upregulation of spontaneous lytic
reactivation (Bellare and Ganem, 2009). miRNA K1 has been
proposed to target IkB; by enhancing NF-kB activation, this
targeting could also stabilize latency (Lei et al., 2010). (miRK1
has also been shown to regulate p21 expression and affect
sensitivity to p53-mediated growth arrest [Gottwein and Cullen,
2010].). By contrast, another viral miRNA, miRK5, targets
a host function (BCLAF-1) that suppresses lytic reactivation
2-fold; as a result, this miRNAmodestly enhances such reactiva-
tion (Ziegelbauer et al., 2009). The latter phenotype, whose
molecular basis is still not understood, probably contributes to
maintaining the reversibility of latency. It’s important to note
that viral miRNAs are not the primary determinants of the regula-
tion of latency—that role belongs to the transcriptional regulation
of RTA. Rather, they appear to be ancillary effectors that allow for
fine-tuning of the process.
MHV68 Latency and Its Control
An Overview
MHV68 (also referred to as g-HV68 and MuHV4) was first iso-
lated 30 years ago from bank voles and field mice in Eastern
Europe (Blaskovic et al., 1980). The MHV genome is estimated
to have diverged from its primate counterpart ca. 60million years
ago (McGeoch et al., 2005). Its sequence reveals that it is 118 kb
in length and is predicted to encode 79 ORFs (Virgin et al., 1997)
(see Figure 4, in which the MHV68 genome is aligned with that of
KSHV). Viral growth in vitro is rapid and efficient, generating
high-titer viral stocks. In addition, genetic systems based on
homologous recombination allow facile genetic engineering
of MHV68, making possible the construction of mutant viruses
for virtually any viral gene. Indeed, transposon mutagenesis
analyses have already pinpointed most of the genes that are
dispensable for lytic growth in vitro and identified genes that
selectively affect replication and pathogenesis in the intact
host (Moorman et al., 2004; Song et al., 2005).
Although MHV68 has been shown to latently infect macro-
phages and dendritic cells, we will limit our discussion here to
MHV68 latency in B cells. Both primary B cells as well as estab-
lished murine B cell lines are difficult to efficiently infect with
MHV68 and are not generally permissive for virus replication.
However, several established B cell lines have been shown to
support latency (Forrest and Speck, 2008; Liang et al., 2009).
Clearly, the major asset of the MHV68 system is the availability
of a robust and genetically manipulable animal model in which
both latency and lytic reactivation occur reproducibly. MHV68
readily infects laboratory mice (Musmusculus), in which it estab-
lishes a chronic infection that is harbored for life. Most experi-
mental infections are initiated by intranasal or intraperitoneal
inoculation. Following intranasal infection, lytic replication
occurs transiently in the respiratory tract and spleen, but is
generally cleared by about 2 weeks postinfection, leading to
latency establishment in B cells (predominantly in the spleen),
macrophages (especially in the peritoneum), and splenic den-
dritic cells (Flan˜o et al., 2000; Weck et al., 1999b). Following peri-
toneal infection, lytic replication also transiently occurs in the
spleen, followed by establishment of latency in the same sitesCell Host & Microbe 8, July 22, 2010 ª2010 Elsevier Inc. 107
Figure 4. Alignment of the MHV68 and KSHV Genomes
Alignment of the MHV68 and KSHV genomes, depicting the large blocks of conserved genes, interspersed with genes unique to each virus (KSHV-unique genes
are denoted with K prefixes, MHV-specific genes with M prefixes). There is one exception to this designation: the M3 gene of MHV68 is homologous to both K3
and K5 of KSHV. Shown below are data compiled from two independent transposonmutagenesis screens of theMHV68 genome, which identified genes involved
in virus replication in permissive fibroblasts. Red arrows depict genes essential for replication, while orange arrows depict genes that play an important role in
replication but are not essential. Green arrows depict genes that are dispensable for virus replication in tissue culture.
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large numbers of latently infected cells are generated, with up to
1 in 100 splenocytes showing evidence of latency. At this time,
up to 10% of these cells are capable of spontaneous re-entry
into the lytic cycle, as judged by their ability to generate infec-
tious centers when cultured on permissive mouse embryo fibro-
blast (MEF) monolayers (Sunil-Chandra et al., 1992; Weck et al.,
1999a, 1999b). However, with the passage of time (and the
development of antiviral immune responses), the profile of
latently infected cells changes.
Early in latency, virus infection is found in naive (sIgD+),
germinal center (GL7+/CD95+), and isotype-switched memory
B cells (Flan˜o et al., 2002; Willer and Speck, 2003) as well as
macrophages and dendritic cells. However, as time progresses,
infection of naive B cells rapidly wanes and is largely absent by
3 months postinfection (Willer and Speck, 2003). Concomitant
with the loss of MHV68-infected naive B cells is a significant
overall contraction of the pool of latently infected splenocytes,
from a peak of ca. 1 in 100 cells to a steady state level of ca. 1
in 10,000 cells by 3 months postinfection. The contribution of
non-B cell reservoirs to the pool of latently infected splenocytes
also rapidly diminishes and is nearly nonexistent by 3 months
postinfection (Willer and Speck, 2003). Thus, like EBV, MHV68
ultimately is found nearly exclusively in isotype-switched B cells
that have undergone a germinal center reaction and appear to108 Cell Host & Microbe 8, July 22, 2010 ª2010 Elsevier Inc.reflect memory B cells. This argues that persistence in memory
B cells may be a common strategy utilized by many/most
g-herpesviruses.
Role of NF-kB in MHV68 B Cell Latency
Normal B cell responses are dependent on the activation of
NF-kB for the initiation of a germinal center reaction, where
both antigen stimulation through the B cell receptor and CD4+
T cell help mediated through CD40 are required. As discussed
above, the EBV LMP-1 and KSHV v-FLIP both act to upregulate
NF-kB activity, which is important for stabilizing the latent state.
Consistent with a role for NF-kB in the establishment of MHV68
latency, inhibiting NF-kB activation triggers MHV68 reactivation
from latency (Brown et al., 2003). In addition, overexpression of
the NF-kB subunit p65 inhibits MHV68 lytic replication in
permissive cells, further arguing for an active role of NF-kB in
promoting latency by suppressing virus replication (Brown
et al., 2003). Moreover, a recombinant MHV68 expressing
a mutant form of IkBa (IkBaM) that prevents NF-kB activation
severely inhibits establishment of MHV68 latency in the mouse
spleen (Krug et al., 2007), supporting the importance of NF-kB
activation in the establishment of chronic MHV68 infection
in vivo.
A shortcoming of many of the above studies has been the reli-
ance on overexpression of NF-kB subunits. However, a recent
study (Krug et al., 2009) examining the role of the NF-kB p50
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infected with MHV68 provides more definitive evidence for
the role of NF-kB in suppressing reactivation of MHV68. In this
study, the absence of p50 resulted in ongoing persistent virus
replication in the lungs of infected mice at times when no virus
replication could be detected in wild-type infected mice. This
was not due to immune defects in p50 null mice, since it was
also observed in mixed bone marrow chimeric mice reconsti-
tuted with both p50-sufficient and p50-deficient bone marrow.
The latter result argues for a cell-intrinsic role of p50 in suppress-
ing MHV68 reactivation from latency. A role of NF-kB in sup-
pressing MHV68 reactivation is further supported by analyses
of chronic MHV68 infection in CD40/ mice. B cells lacking
CD40 signaling display reduced NF-kB activity; not surprisingly,
significantly higher levels of persistent virus replication in the
lungs of these mice can be detected at 2–3months postinfection
(Willer and Speck, 2005). Furthermore, in mixed bone marrow
chimeric mice reconstituted with wild-type and CD40/ bone
marrow, MHV68 infection of CD40-deficient B cells is lost over
time, arguing for an active role of CD40 signaling in maintaining
latency (Kim et al., 2003). Thus, just as in EBV and KSHV infec-
tion, NF-kB activation plays a critical role in latency in MHV68
infection.What ismissing in theMHV68 case is an understanding
of exactly how the virus manipulates the NF-kB pathway—i.e.,
which viral gene products are involved and how they act.
However, there are some discordant notes in this symphony.
It has been reported that the MHV68 LANA protein may downre-
gulate NF-kB activation, a function mediated through an uncon-
ventional SOCS-box motif in LANA (Rodrigues et al., 2009). This
motif can target ubiquitination and proteosomal degradation of
p65/RelA through assembly of an ElonginC/Cullin5/SOCS-like
E3 ligase complex. Notably, mutations in the MHV68 LANA
protein that disrupt this function prevent efficient establishment
ofMHV68 latency—this is counter to the above data that upregu-
lation of NF-kBpromotes latency and suggests that there ismore
to understand about the role of NF-kB in the modulation of
latency. Similarly, in KSHV, Grossmann and Ganem (2008) found
that not all cell lines display enhanced lytic reactivation following
inhibition of NF-kB activation. At present, no explanation exists
to reconcile these discrepancies.
The Latency Program of MHV68
Because (until rather recently) only a single B cell line harboring
MHV68 has been widely available for study, there has been
a paucity of in vitro latency systems that would allow rigorous,
high-resolution characterization of the transcriptional program,
as has been done for EBV and KSHV. As such, it has been harder
to reach agreement on the details of the latent transcriptional
program(s) in MHV68, which are dependent upon RT-PCR anal-
yses of latently infected splenocytes and peritoneal macro-
phages. Spontaneous lytic replication and/or abortive infection
in minor subpopulations of such cells, however, complicate
interpretation of such analyses. For this reason, and for brevity,
in this review we will not survey the complete roster of MHV68
gene products that have been posited to play roles in the estab-
lishment or disruption of latency. Some of these genes—for
example, those encoding homologs of G protein-coupled recep-
tors or antiapoptotic Bcl2 protein—have interesting or subtle
effects on reactivation from latency, but their homologs in EBV
or KSHV are clearly lytic-cycle genes, raising questions as tohow to interpret their functions in MHV68. Rather than confront
this interpretive dilemma, we will focus instead on the small
number of MHV68 genes that (1) are expressed by RT-PCR in
latently infected tissues and (2) have homologs in other
g-herpesviruses that are clearly assigned to the latency
program. Chief among these are LANA and v-cyclin (see below).
However, it bears mentioning that MHV68 encodes a number
of unique genes not conserved in other g-herpesviruses that can
have pronounced effects on latency and reactivation (e.g., M1
and M2). M1 is a secreted protein that appears to have super-
antigen-like activity, inducing the expansion and activation of
Vb4+ CD8+ T cells (Evans et al., 2008). M1 stimulation results
in the expression of a number of cytokines from Vb4+ CD8+
T cells, including high levels of IFN-g, a cytokine shown to sup-
press MHV68 reactivation from infected macrophages (Steed
et al., 2007). Notably, a null mutation in the M1 gene results in
a virus that hyperreactivates from macrophages (Clambey
et al., 2000). M2 is a putative scaffolding protein with likely roles
in modulation of signal transduction (Herskowitz et al., 2008;
Pires de Miranda et al., 2008) and suppression of DNA-
damage-induced apoptosis (Liang et al., 2006). Additionally,
M2 is a potent inducer of host IL-10 production, an activity that
leads to enhanced survival and proliferation of primary B cells
as well as suppression of host immune responses. M2 expres-
sion is also linked to the promotion of plasma cell differentiation
(Liang et al., 2009), which in MHV68, as in EBV and KSHV, can
trigger lytic reactivation (see discussion of virus reactivation
below).
LANA. The MHV68 LANA homolog (referred to as mLANA) is
significantly shorter than the KSHV LANA, being largely com-
posed of the C-terminal domain that is conserved among the
other characterized LANA homologs and lacking the long
internal repeat and amino-terminal domains present in the
KSHV LANA. MHV68 LANA null viruses are severely compro-
mised in establishing latency in the spleen following intranasal
inoculation, consistent with the proposed role of LANA homo-
logs in maintenance of the viral episome during latency (Fowler
et al., 2003; Moorman et al., 2003b). It is possible to force
the establishment of a chronic infection with the mLANA null
MHV68 by either altering the route of inoculation of virus or
infecting immunocompromised mice (Paden et al., 2010). How-
ever, under these experimental conditions, the viral genome
appears to be integrated and the infected B cells are unable
to reactivate virus. Thus, this is probably best described as an
abortive infection, although the presence of splenocytes
harboring viral genome persists for many months following
infection.
The mLANA null MHV68 also exhibits alterations in acute virus
replication in the lungs following intranasal inoculation (Moorman
et al., 2003b). This defect in virus replication can be partially
mimicked under some infection conditions in tissue culture (Forr-
est et al., 2007) and correlates with significant dysregulation in
viral lytic gene expression. The mLANA null MHV68 exhibits
a substantially more rapid and higher-level induction of early viral
gene expression, consistent with a role for LANA in repression of
lytic genes posited in KSHV (Li et al., 2008). However, LANA null
MHV68 infection also triggers a more rapid induction of cell
death, likely due to the loss of LANA’s ability to antagonize
p53. The net result is that early cell death diminishes the ultimateCell Host & Microbe 8, July 22, 2010 ª2010 Elsevier Inc. 109
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replication kinetics of the virus. Thus, in vivo studies with
MHV68 affirm biologic roles for most of the biochemical activities
previously ascribed to KSHV LANA on the basis of studies of the
recombinant protein, including (1) episome maintenance, (2)
repression of at least some lytic genes, and (3) inhibition of
p53-mediated apoptosis.
V-Cyclin. Given the confusion about the biological role of
KSHV v-cyclin (see above), it is hoped that further clues to
its function can be gleaned from examination of its MHV68
homolog. MHV68 v-cyclin, however, displays some important
biochemical differences from its KSHV counterpart. Both are
fully functional as CDK activators, but the MHV68 protein prefer-
entially binds and activates CDK2 (and can interact in vitro with
CDK1), while KSHV v-cyclin preferentially binds CDK6, but can
also bind CDK2 and CDK4. The crystal structure of the MHV68
v-cyclin in complex with CDK2 has been determined and
revealed that the MHV68 v-cyclin makes several novel contacts
with CDK2 compared toCDK2 interactionwith cyclin A, but over-
all its activation of CDK2 is likely similar to cyclin A (Card et al.,
2000). The MHV68 v-cyclin is abundantly expressed during viral
replication from a promoter mapping just upstream of the
v-cyclin coding exon (ORF-72). In addition, spliced v-cyclin tran-
scripts have been identified in the MHV68 latently infected S11 B
lymphoma cell line, driven by two distinct promoters, one
mapping within the TRs (P1) and another mapping just outside
the TRs (P2) (Allen et al., 2006). This is reminiscent of EBV latency
transcription, where the EBNA gene promoter Wp is encoded
with the major internal repeat and thus present in many copies
like the P1 promoter, while Cp, like P2, is present in a single
copy being encoded outside of the repeat. Notably, like KSHV,
transcripts initiating from P1 or P2 are alternatively spliced to
either the LANA or v-cyclin coding exons. Importantly, spliced
LANA and v-cyclin transcripts could also be detected using
RNA prepared from splenocytes at day 16 postinfection, indi-
cating that these transcripts are expressed in the context of
MHV68 infection of mice (Allen et al., 2006).
Several mutant versions of MHV68 cyclin have been con-
structed in the viral genome, and their phenotypes are somewhat
variable, depending on the route of infection and dose of virus
administered. Following high-dose (106 pfu) intraperitoneal inoc-
ulation, v-cyclin null MHV68 mutants exhibited wild-type levels
of acute virus replication in the spleen and normal establishment
of latency in both the spleen and peritoneum. However, the
v-cyclin null mutants exhibited a profound defect in virus reacti-
vation from latently infected peritoneal macrophages at 6 weeks
postinfection (van Dyk et al., 2000). A related study using
a v-cyclin null MHV68, in which a b-galactosidase expression
cassette was inserted in place of the v-cyclin ORF, exhibited
defects in both acute virus replication and reactivation from
latently infected splenocytes (Hoge et al., 2000). Further studies
using both v-cyclin null virus and v-cyclin CDK-binding mutants
revealed acute replication defects in the lungs following low-
dose (1000 pfu) intranasal inoculation, a phenotype that was
more severe when the viruses were administered intranasally
versus intraperitoneally (Upton and Speck, 2006). In addition,
following intranasal inoculation, neither the v-cyclin null mutant
nor the CDK-binding mutant viruses induced splenomegaly.
Surprisingly, while the v-cyclin null mutant was highly attenuated110 Cell Host & Microbe 8, July 22, 2010 ª2010 Elsevier Inc.for reactivation from macrophages, neither of the CDK-binding
mutants was impaired for reactivation from this latency reservoir.
The latter argues that the v-cyclin has CDK-independent
functions that play a role in virus reactivation from peritoneal
macrophages.
While it’s difficult to know how to translate these results to
KSHV infection, it seems clear that v-cyclin consistently plays
a role in reactivation of MHV68 from latency andmay affect other
portions of the life cycle in a context-dependent way. The chal-
lenge for the future is to determine (1) how many of these activ-
ities relate to CDK activation, (2) how CDK activation engenders
these activities, and (3) whether any v-cyclin actions are due to
other biochemical activities not dependent upon CDKs.
Exit from Latency: Common Themes in g-Herpesvirus
Lytic Reactivation
Entry into the g-herpesvirus lytic replication cycle requires the
expression of the highly conserved immediate-early gene
ORF-50 in KSHV and MHV68 (BRLF1 in EBV), which encodes
a transcriptional activator referred to as RTA (Zalani et al.,
1996; Ragoczy et al., 1998; Sun et al., 1998; Lukac et al.,
1998). RTA is a sequence-specific DNA-binding protein that
can function as a transcriptional activator, and null mutations
engineered into full-length EBV, KSHV, or MHV68 genomes
result in viruses that cannot reactivate from latency (Xu et al.,
2005; Lukac et al., 1999). Conversely, recombinant MHV68
strains bearing constitutively active RTA genes cannot establish
latency and are locked into obligate lytic replication (Rickabaugh
et al., 2004). RTA’s transactivation function controls reactivation
by turning on the expression of numerous replication-associated
genes. In the case of EBV, there is an additional immediate-early
transcriptional activator, Zta, encoded by the BZLF1 gene that is
essential for full expression of the lytic cascade leading to
production of progeny virus (Feederle et al., 2000). Typically,
virus reactivation from latently infected B cell lines can be
induced in vitro by various chemical stimuli, such as phorbol
esters or sodium butyrate, which are thought to act by activating
expression of the RTA (and Zta) genes (see Speck et al., 1997);
triggers of a variety of other signaling pathways can also induce
lytic reactivation (Yu et al., 2007a). While high-affinity binding
sites have been defined for both EBV and KSHV RTA (Song
et al., 2003), not all RTA-responsive genes have obvious RTA-
binding sites. Thus, it is likely that the interaction of RTA with
cellular transcription factors aids in activation of target genes,
and indeed, a number of such interactions have been docu-
mented in KSHV, e.g., with C/EBPa, Oct-1, and others (see
Deng et al. [2007] for review). In the case of KSHV RTA, a partic-
ularly important interaction is with RBP-Jk (or CSL-1), the main
effector of the Notch signaling pathway; ablation of RBP-Jk
does not appear to affect establishment of KSHV latency but effi-
ciently blocks lytic reactivation (Liang et al., 2002; Liang and
Ganem, 2003). This is a very different role for RBP-Jk than is
observed in EBV latency, where it plays a central role in control-
ling latency-associated gene expression. However, at least one
report suggests that a latent KSHV protein (LANA) may also
interact with RBP-Jk (Lan et al., 2005).
Until recently, it was largely assumed that expression of the
immediate-early genes was impaired due to the absence of crit-
ical positive regulators in the cells in which latency is established.
However, recent data on the early phases of EBV infection in B
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infection, incoming virion DNA is unmethylated. In the case of
EBV, this is important because Zta binds preferentially to recog-
nition sites that are CpG methylated (Bhende et al., 2004). It was
recently determined that, contrary to expectations, there is
a burst of Zta synthesis following de novo infection of B cells
(Kalla et al., 2010). However, this burst of Zta expression does
not trigger virus replication because Zta activation of a number
of essential viral replication genes does not occur from the
unmethylated viral genome. As the EBV genomes become chro-
matinized, CpG methylation proceeds—but apparently, by the
time most Zta target sites are methylated, there are no longer
sufficient levels of ‘‘active’’ Zta to trigger transcription of these
genes. Expression of Zta has been shown to be quelled by the
formation of repressive complexes on the BZLF1 promoter,
most notably through binding of phosphorylated MEF2D (which
binds to three sites within the Zta promoter) and recruitment of
histone deacetylases (Bryant and Farrell, 2002). Thus, epigenetic
marking of the EBV genome plays a central role in regulating
virus replication during the establishment of latency. It should
also be pointed out that the core promoter driving Zta expression
is devoid of CpG dinucleotides and thus is never methylated.
This may be a key feature that allows the initial expression of
Zta following appropriate reactivation stimuli. Methylation of
the RTA promoter has also been detected in KSHV lalency
(Chen et al., 2001). More extensive studies of epigenetic marks
in latent KSHV chromatin are now underway, and the most
recent results show widespread repressive marks (e.g., histone
H3K27 trimethylation) in latent chromatin (Gu¨nther and Grundh-
off, 2010). Interestingly, the kinetics of acquisition of DNA meth-
ylation suggest that CpG methylation itself may not play as
prominent a role in KSHV as in EBV in the early repression of lytic
gene expression (Gu¨nther and Grundhoff, 2010).
In addition to these epigenetic effects, NF-kB activation plays
an important role in all three viruses in controlling lytic reactiva-
tion and stabilizing latency (Brown et al., 2003; Grossmann and
Ganem, 2008; Ye et al., 2008). As previously noted, all three
viruses encode activators of NF-kB in their latency programs.
In EBV, activation of NF-kB by LMP-1 contributes to control of
lytic reactivation via a direct inhibitory interaction of p65 with
Zta (Gutsch et al., 1994). In KSHV, recent work indicates that
p65 can directly interact with RBP-Jk and interfere with the
recruitment of RTA/RBP-Jk complexes to essential target pro-
moters in the lytic transcriptome (Izumiya et al., 2009).
Although many exogenous stimuli can trigger lytic replication
in culture, recent data have provided an important insight into
a shared pathway that likely plays a critical role in g-herpesvirus
reactivation in vivo. Expression of factors known to stimulate
plasma cell differentiation can lead to EBV, KSHV, and MHV68
reactivation. Chief among these is XBP-1s, which also plays
a central role in the cellular unfolded protein response; XBP-1s
expression can induce both EBV and KSHV to enter the lytic
cycle (Bhende et al., 2007; Laichalk and Thorley-Lawson,
2005; Sun and Thorley-Lawson, 2007; Yu et al., 2007b; Wilson
et al., 2007). In vivo, XBP-1s expression is induced by BLIMP-1,
the master regulator of plasma cell differentiation. XBP-1s is
a member of the CREB family of transcription factors and, in
the case of EBV reactivation, has been shown to bind a site in
the EBV Zta promoter that is known to bind CREB and AP-1proteins. Thus, EBV, KSHV, and MHV68 are apparently able to
usurp plasma cell differentiation to turn an antibody-producing
cell into a virus factory. The big remaining question is: what regu-
lates differentiation of latently infected B cells to plasma cells?
While this remains unknown for EBV and KSHV, an important
insight has been gained from studies on the control of MHV68
reactivation. These studies have identified a viral protein (M2)
that can drive plasma cell differentiation (Liang et al., 2009).
The absence of a functional M2 gene results in a severe defect
in virus reactivation from splenic B cells, which correlates with
the absence of virus-infected plasma cells (Liang et al., 2009).
This suggests the tantalizing possibility that plasma cell differen-
tiation of latently infected B cells may be regulated by the virus
rather than by antigen stimulation. However, since there is no
obvious homolog of MHV68 M2 in either EBV or KSHV, it is
unclear whether these viruses encode this function.Coda
The analysis of the latency programs of these three g-herpesvi-
ruses reveals how superbly adapted they are to the lymphoid
systems of their hosts. At the single-cell level, they have evolved
elegant mechanisms to assure extrachromosomal genomic
persistence as autonomous replicons and by using viral proteins
to tether their genomes to host chromosomes during mitosis.
Other viral proteins manipulate cellular signaling pathways,
including those that activate NF-kB and those that mimic B cell
receptor signaling, both of which are known to provide signals
to promote prolonged survival of the latently infected cell.
In the two cases where studies have been done on intact hosts,
these activities are thought to allow the latent viral genome to
access its ultimate reservoir, the long-lived memory B cell, an
ideal locale from the point of view of assuring long-term persis-
tence. In addition to extending host cell life span, latent gene
products also act to repress lytic functions, activate latent
promoters, and (most likely) induce or regulate epigenetic marks
that influence viral gene regulation. All of these activities are set
up in a delicate balance, so as to maintain reasonable stability in
latency without becoming locked into it irreversibly. As a result,
spontaneous reactivation is frequent enough to promote efficient
spread of infection between individuals, while ongoing latency
allows the infection to persist lifelong in each newly infected
subject. It’s a winning formula for the pathogen, though not
a simple one—and one from which we can continue to expect
surprises as we begin to understand it more fully in the years
to come.ACKNOWLEDGMENTS
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